Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 35Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 26Multiple Myeloma 24Leukemia, Myeloid, Acute 21Recurrence 19Neoplasm Metastasis 17Colorectal Neoplasms 17Ovarian Neoplasms 15Lymphoma, Non-Hodgkin 15Carcinoma, Renal Cell 15Melanoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Follicular 12Urinary Bladder Neoplasms 11Myelodysplastic Syndromes 11Lung Neoplasms 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Hematologic Neoplasms 10Carcinoma, Hepatocellular 10Stomach Neoplasms 9Prostatic Neoplasms 9Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Adenocarcinoma 9Thyroid Neoplasms 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Has announcements × Advanced Non-small Cell Lung Cancer × Clear all
NCT05099172 2026-05-13

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Bayer

Phase 1/2 Active not recruiting
370 enrolled 1 FDA
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡